The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

Boston-based Bicara launched in 2021, and is a subsidiary of Indian pharma company Biocon, which provided its seed funding. Bicara is also studying ficerafusp alfa, its lead candidate, in anal cancer ...

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.

Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

ExpressionEdits' Genetic Syntax Engine platform is designed to enhance gene expression within gene therapies by restoring introns.

New three-month data from a study of non-human primates underpins the biotech firm's decision to amend the small interfering RNA program.

NEW YORK – Galapagos said on Monday that it has partnered with NecstGen, a contract development and manufacturing organization (CDMO), to support decentralized manufacturing of Galapagos' cell therapy ...

The biopharma company, which is developing cell therapies for cancers and autoimmune diseases, said it will use the proceeds for working capital.

Ibex Prostate Detect is designed to help pathologists catch small and rare cancers in whole-slide images from tissue biopsies that they might've missed.

Conservative supporters of government deregulation want to do away with state-imposed licensing requirements, a move genetic counselors say will harm patients.

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can ...